08:45 AM EDT, 03/19/2025 (MT Newswires) -- Immunovant ( IMVT ) shares were nearly 7% lower in recent premarket activity after the company said it is not planning to seek regulatory approval for batoclimab as a treatment for myasthenia gravis or chronic inflammatory demyelinating polyneuropathy.

The immunology company said it will wait to make a final decision about regulatory submissions for batoclimab until the results of ongoing phase 3 studies of the drug candidate in thyroid eye disease are available.

The company reported Wednesday that topline results from a phase 3 study of batoclimab in myasthenia gravis met a primary endpoint.

Shares of Roivant (ROIV), which is the majority owner of Immunovant ( IMVT ), were 1.3% lower in recent premarket activity.